Tags : Celiac Disease

Takeda Acquires Exclusive Worldwide License Rights for COUR’s CNP-101 to

Shots: COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study In Dec’2015, Takeda and COUR collaborated to develop therapies for celiac disease, provided Takeda an exclusive option to acquire a WW license […]Read More

Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to

Shots: Amgen to make $20M investment in Provention and also has option to license AMG-714 (after completion of P-IIb), if exercised will pay $150M as upfront plus milestones and royalties to Provention Provention to fund and conduct the P-IIb trial for PRO-015 (AMG 714) and holds commercialization rights (if not exercised by Amgen) while giving […]Read More